Type 2 diabetes with ASCVD — RCPSC IM MCQ
Instant feedback + full explanation. One question, done properly.
Educational content. Not a substitute for clinical judgement or local policy.
Reveal the answer and explanation
Correct answer: C — Add an SGLT2 inhibitor or GLP-1 receptor agonist with cardiovascular benefit
In type 2 diabetes with established cardiovascular disease, glucose-lowering therapy should include an agent with proven cardiovascular benefit, such as an SGLT2 inhibitor or GLP-1 receptor agonist when appropriate.
Reference: Diabetes Canada clinical practice guidelines